Lifecycle position of every product, transparent readiness scorecards and the integrated launch roadmap.
Vantrexa EU5 & Japan readiness
Active scorecards
Dimensions without data
Stage 1
Preclinical
Stage 2
Early clinical development
Stage 3
Late clinical development
Stage 4
Regulatory submission
Stage 5
Pre-launch
Stage 6
Launch
Stage 7
Early post-launch
Stage 8
Mature post-launch
Stage 9
Lifecycle extension
Stage 10
Discontinuation
January 2026 to March 2027, grouped by milestone category.
Dashed line marks today (15 Sept 2026). Dot colour follows status: completed (green), in progress (blue), planned (grey), at risk (amber), blocked (red). Outer ring uses the product colour.
| Date | Milestone | Category | Product | Country | Status |
|---|---|---|---|---|---|
| 12 Mar 2026 | FDA approval (1L PD-L1 ≥ 50% NSCLC) | Regulatory | Vantrexa | United States | Completed |
| 01 Apr 2026 | US launch | Country launch | Vantrexa | United States | Completed |
| 12 May 2026 | Competitor TIGIT Phase III readout (negative) | Competitor | Vantrexa | — | Completed |
| 31 May 2026 | ASCO 2026 — OS data presented | Congress | Vantrexa | — | Completed |
| 01 Jun 2026 | Sequencing advisory board | Advisory board | Vantrexa | — | Completed |
| 15 Aug 2026 | EU field certification complete | Field readiness | Vantrexa | — | Completed |
| 31 Aug 2026 | SEQUENCE-RW contract executed | Evidence | Vantrexa | — | Blocked |
| 18 Sept 2026 | EMA CHMP positive opinion | Regulatory | Vantrexa | — | In progress |
| 30 Sept 2026 | All 24 standard responses approved | Medical information | Vantrexa | — | In progress |
| 17 Oct 2026 | ESMO 2026 presentations | Congress | Vantrexa | — | Planned |
| 20 Oct 2026 | OS manuscript online publication | Publication | Vantrexa | — | Planned |
| 21 Oct 2026 | Pathology education ES/IT | Education | Vantrexa | — | Planned |
| 22 Oct 2026 | JSMO symposium | Congress | Vantrexa | Japan | Planned |
| 06 Nov 2026 | ASN Kidney Week late-breaking oral | Congress | Nephrada | — | Planned |
| 20 Nov 2026 | EC marketing authorisation | Regulatory | Vantrexa | — | Planned |
| 01 Dec 2026 | Germany launch | Country launch | Vantrexa | Germany | Planned |
| 08 Dec 2026 | UK launch (MHRA) | Country launch | Vantrexa | United Kingdom | Planned |
| 15 Dec 2026 | France early access | Access | Vantrexa | France | Planned |
| 20 Dec 2026 | PMDA approval | Regulatory | Vantrexa | Japan | At risk |
| 20 Dec 2026 | PMDA approval | Regulatory | Vantrexa | Japan | At risk |
| 01 Feb 2027 | Japan launch | Country launch | Vantrexa | Japan | Planned |
| 01 Feb 2027 | Japan launch | Country launch | Vantrexa | Japan | Planned |
| 28 Feb 2027 | FDA accelerated approval decision | Regulatory | Nephrada | United States | Planned |
| 15 Mar 2027 | US launch | Country launch | Nephrada | United States | Planned |
How readiness is scored (PRD §18.5)